Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA approves Blincyto to treat relapsed or refractory B-cell precursor ALL

Dec. 4, 2014

Phase I results reported for glioma vaccine SurVaxM

Dec. 4, 2014

Imugene updates preclinical findings for HER-Vaxx

Dec. 4, 2014

Unum Therapeutics initiates phase I trial of antibody-coupled T-cell receptor therapy

Dec. 3, 2014

GlaxoSmithKline presents preclinical data for the anti-HER3 antibody GSK-2849330

Dec. 2, 2014

Promising phase IIb results presented from the TIME trial evaluating TG-4010 in NSCLC

Dec. 2, 2014

First-in-human study of OBT-357 begins in acute myeloid leukemia

Nov. 26, 2014

Primary endpoint met in phase II study of TriMix-DC-MEL melanoma vaccine

Nov. 25, 2014

Amgen terminates all Amgen-sponsored studies of rilotumumab in advanced gastric cancer

Nov. 25, 2014

First clinical data showed that KTN-3379 is well tolerated in advanced solid tumors

Nov. 25, 2014

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...